2024 / Randomized trial against no treatment

Read the endpoint behind the headline.

How was a cheek-wrinkle response defined?

Source access: publication abstract

The study#

Design: Randomized trial against no treatment
Population: Immune-competent adults over 21
Follow-up / endpoint: 12 months
Source: Journal of Drugs in Dermatology, 2024 · PMID 38206151

What the authors found#

A one-grade or greater improvement at rest in both cheeks occurred in 71.6% of treated participants and 26.1% of controls at month 12.[1]

month-12 responders · both cheeks

Sculptra71.6%

No treatment26.1%

Each bar uses the same 0–100% scale. Values are study-specific; confidence intervals are not supplied here.

Editorial interpretation

Why it is interesting#

This supports the studied treatment course and cheek-wrinkle outcome.

Pair the responder rate with the treatment course and the actual comparator.

What it cannot tell us#

No-treatment control, not another injectable.
Up to four treatment sessions were allowed; do not describe this as a single-injection result.

Selection for this library reflects educational interest. It is not a systematic search, formal certainty grade, or complete account of the literature.

Funding & commercial context#

Consult the publication's full text for funding and conflict-of-interest statements; the abstract does not provide a complete disclosure.

Continue with the product

Sculptra ↗

Source & citation#

Sculptra — randomized cheek-wrinkle trial ↗

Checked 2026-09-06 · Journal of Drugs in Dermatology, 2024 · PMID 38206151. Cite the original publication when discussing its results; this page is an interpretation.

Aesthetic Pass. Read the endpoint behind the headline. Product Atlas research interpretation 2026.09.06.1. https://aestheticpass.com/products/studies/sculptra-cheek-wrinkle-trial/